Opinion|Videos|October 7, 2024
Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC
Key Takeaways
- PD-1/PD-L1 pathways are pivotal in cancer immunotherapy, enabling tumor immune evasion by inactivating T-cells through receptor-ligand interactions.
- Investigational agents in BCG-naive and unresponsive settings include gene therapy and intravesical treatments, targeting enhanced immune activation.
Panelists discuss how the PD-1/PD-L1 pathway plays a crucial role in cancer immunotherapy, outlining its mechanisms of action and highlighting the agents currently being investigated for patients who are BCG-naive or unresponsive, including gene therapy and intravesical options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of the PD-1/PD-L1 pathways in cancer immunotherapy?
- What are their mechanisms of action?
What agents are being investigated in the BCG-naive and unresponsive setting? Gene therapy, intravesical?
Advertisement
Related to this article
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Casdatifan shows activity across treatment settings in advanced ccRCC
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5